Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
NEW YORK, June 12, 2026 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the U.S. Food and Drug Administration (FDA) to approve Tzield for use in individuals ages 8-17 within eight weeks of a...
NEW YORK, June 12, 2026 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the U.S. Food and Drug Administration (FDA) to approve Tzield for use in individuals ages 8-17 within eight weeks of a...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.